Enveric Net Debt vs Capital Stock Analysis
ENVB Stock | USD 0.34 0.01 2.86% |
Enveric Biosciences financial indicator trend analysis is much more than just examining Enveric Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enveric Biosciences is a good investment. Please check the relationship between Enveric Biosciences Net Debt and its Capital Stock accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.
Net Debt vs Capital Stock
Net Debt vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enveric Biosciences Net Debt account and Capital Stock. At this time, the significance of the direction appears to have weak relationship.
The correlation between Enveric Biosciences' Net Debt and Capital Stock is 0.35. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Enveric Biosciences, assuming nothing else is changed. The correlation between historical values of Enveric Biosciences' Net Debt and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Enveric Biosciences are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Net Debt i.e., Enveric Biosciences' Net Debt and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.35 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most indicators from Enveric Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enveric Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.As of November 21, 2024, Selling General Administrative is expected to decline to about 6.3 M. The current year's Tax Provision is expected to grow to about (1.4 M)
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 25.9M | 20.0M | 16.4M | 17.3M | Cost Of Revenue | 681.6K | 435.2K | 408.0K | 387.6K |
Enveric Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Enveric Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enveric Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 25.0M | 4.1M | 26.7M | 19.6M | 4.3M | 4.1M | |
Other Current Liab | 4.8M | 681.3K | 1.2M | 3.4M | 1.1M | 1.9M | |
Total Current Liabilities | 14.4M | 681.3K | 2.1M | 4.0M | 2.3M | 3.7M | |
Total Stockholder Equity | 10.6M | 3.4M | 22.3M | 14.7M | 2.0M | 1.9M | |
Net Debt | 4.4M | (1.6M) | (17.2M) | (17.7M) | (2.3M) | (2.2M) | |
Retained Earnings | (40.5M) | (11.8M) | (60.7M) | (79.2M) | (96.5M) | (91.7M) | |
Accounts Payable | 4.7M | 681.3K | 683.4K | 463.3K | 1.2M | 1.3M | |
Cash | 431.4K | 1.6M | 17.4M | 17.7M | 2.3M | 2.3M | |
Non Current Assets Total | 17.4M | 1.8M | 9.0M | 1.1M | 718.3K | 682.4K | |
Cash And Short Term Investments | 431.4K | 1.6M | 17.4M | 17.7M | 2.3M | 2.4M | |
Net Receivables | 8.8M | 7.9M | 6.4M | 224.6K | 258.3K | 245.4K | |
Common Stock Shares Outstanding | 26.4K | 115.1K | 472.3K | 1.4M | 2.2M | 2.3M | |
Liabilities And Stockholders Equity | 25.0M | 4.1M | 26.7M | 19.6M | 4.3M | 4.1M | |
Non Current Liabilities Total | 2.4M | 4.2M | 9.6M | 0.0 | 2.3M | 527.1K | |
Other Current Assets | 783.6K | 1.4M | 761.7K | 1.3M | 1.1M | 1.1M | |
Other Stockholder Equity | 51.0M | 15.2M | 82.7M | 94.4M | 99.0M | 103.9M | |
Total Liab | 14.4M | 681.3K | 4.4M | 4.0M | 2.3M | 2.2M | |
Total Current Assets | 7.6M | 2.3M | 17.7M | 18.4M | 3.6M | 4.2M | |
Intangible Assets | 3.6M | 1.8M | 6.9M | 379.7K | 210.9K | 200.4K | |
Common Stock | 25.2K | 101.0K | 325.8K | 20.8K | 27.4K | 26.0K | |
Accumulated Other Comprehensive Income | 60.0K | (181.3K) | (30.8K) | (536.7K) | (569.7K) | (598.2K) | |
Net Tangible Assets | (65.5K) | (1.8M) | 1.6M | 13.8M | 15.9M | 16.7M | |
Net Invested Capital | 15.5M | 3.4M | 22.3M | 14.7M | 2.0M | 1.9M | |
Net Working Capital | (6.8M) | 1.6M | 15.7M | 14.4M | 1.2M | 909.9K | |
Capital Stock | 29.5K | 133.7K | 325.8K | 20.8K | 27.4K | 26.0K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 37.678 | Quarterly Revenue Growth (0.07) | Return On Assets (0.81) | Return On Equity (2.06) |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.